Publications by Pierre Vogel | EPFL Graph Search

Computational drug development for membrane protein targets

Pierre Vogel, Henning Paul-Julius Stahlberg, Dongchun Ni, Babatunde Edukpe Ekundayo, Shuguang Yuan

The application of computational biology in drug development for membrane protein targets has experienced a boost from recent developments in deep learning-driven structure prediction, increased speed and resolution of structure elucidation, machine learni ...

2024

Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies

Pierre Vogel, Somi Reddy Majjigapu, Jianfei Bai

Targeting cancer cells that are highly dependent on the nicotinamide adenine dinucleotide (NAD+) metabolite is a promising therapeutic strategy. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme catalyzing NAD(+) production. Despit ...

MDPI2023

Ein neuer NAMPT-Inhibitor JJ-08 vermindert Wachstum und Koloniebildung von Pankreaskarzinomzellen in Kombination mit NAPRT-Hemmung

Pierre Vogel, Somi Reddy Majjigapu

KARGER2022

Organic Chemistry and Synthesis Rely More and More upon Catalysts

Pierre Vogel

A few months before the COVID-19 pandemic, Pierre Vogel and Kendall N. Houk published with a new textbook Wiley-VCH, "Organic Chemistry: Theory, Reactivity, and Mechanisms in Modern Synthesis", with a foreword from the late Roberts H. Grubbs. The book demo ...

MDPI2022

Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer

Pierre Vogel, Somi Reddy Majjigapu, Jianfei Bai

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases for which chemotherapy has not been very successful yet. FK866 ((E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide) is a well-known NAMPT (nicotinamide phosphoribos ...

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER2022

Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

Pierre Vogel, Florence Pojer, Somi Reddy Majjigapu

The haem enzyme indoleamine 2,3-dioxygenase 1 (IDO1) catalyses the rate-limiting step in the kynurenine pathway of tryptophan metabolism and plays an essential role in immunity, neuronal function, and ageing. Expression of IDO1 in cancer cells results in t ...

TAYLOR & FRANCIS LTD2022

Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

Pierre Vogel, Florence Pojer, Somi Reddy Majjigapu, George Coukos, Olivier Michielin

The heme enzyme indoleamine 2,3-dioxygenase 1 (IDO1) plays an essential role in immunity, neuronal function, and aging through catalysis of the rate-limiting step in the kynurenine pathway of tryptophan metabolism. Many IDO1 inhibitors with different chemo ...

AMER CHEMICAL SOC2021

Expeditious Asymmetric Synthesis of Polypropionates Relying on Sulfur Dioxide-Induced C-C Bond Forming Reactions

Pierre Vogel

For a long time, the organic chemistry of sulfur dioxide (SO2) consisted of sulfinates that react with carbon electrophiles to generate sulfones. With alkenes and other unsaturated compounds, SO2 generates polymeric materials such as polysulfones. More rec ...

MDPI2021

Anticancer activities of novel nicotinamide phosphoribosyltransferase inhibitor in haematological malignancies

Pierre Vogel, Jianfei Bai

E M H SWISS MEDICAL PUBLISHERS LTD2020

Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)

Pierre Vogel, Florence Pojer, Somi Reddy Majjigapu

Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in the kynurenine pathway of tryptophan metabolism, which is involved in immunity, neuronal function, and aging. Its implication in pathologies such as cancer and neurodegenerative disea ...

AMER CHEMICAL SOC2019